Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.1052W HIGH $572.50
Volume
3.11 K
Value Traded
0.62
Short % Float
124.02%
Days to Cover
1.0
-78.43%Week
-90.76%1 Month
-85.69%3 Month
-97.65%6 Month
-100%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.15 M
EPS (TTM)
-218.81
P/E Ratio
-
Ent. Value
14.79 M
Total Shares
28.66 M
Float Shares
28.65 M
Insiders
0.08%
Institutions
6.04%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
WINT Catalyst Timeline
Dated clinical, regulatory and corporate events for Windtree Therapeutics, Inc.
Past FDA Catalysts and PDUFA Decisions
How WINT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-08-11 | istaroxime | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Istaroxime Small moleculeNCT05975021 | Cardiogenic Shock | Phase 2 | ACTIVE NOT_RECRUITING | 110 | Aug 31, 2026 | ||||||
| Lucinactant Small moleculeCompletedNCT04389671 | COVID-19 | Phase 2 | COMPLETED | 20 | Feb 20, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every WINT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| AEROSURF | Respiratory Distress Syndrome (RDS) in Premature Infants | Phase 2b | 2017-06-29 | n CPAP failure rates: 25 minute 44 percent, 50 minute 44 percent, control 44 percent, 50 minute no interruptions 31 percent, control no interruptions 44 percent; absolute reduction: 13 percent; relative reduction: 30 percentRead More | Windtree Announces Top-Line Results from AEROSURF Phase 2b Clinical Trial for the Treatment of Respiratory Distress Syndrome (RDS) in Premature Infants -Company to Hol d Conference Call Today at 4:30 p.m. EDT- WARRINGTONRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Fraser CraigDirector, Officer (President and CEO) | Buy | 5,431 8,638 held | $0.91 | 10/08/2024 |
Hedge Fund 13F Activity
Hedge Funds invested in WINT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| AFFINITY ASSET ADVISORS, LLC | 0 % | 105.00 K | 42.85 K |
Ownership Trends
WINT Short Interest
Shares sold short, counted twice a month.
124.02%
Short % of Float
of tradable shares sold short
7.7K
Shares Sold Short
0.0% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
15.0K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How WINT ranks across every disease it competes in
Competitive Position is a premium feature
See how WINT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialWINT News
About Windtree Therapeutics, Inc.
Headquarters2600 Kelly Road, Suite 100, Warrington, PA, 18976-3622, United States
BIOPHARMAWATCH ELITE PLUS
Trade the next WINT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime